KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Payables (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Payables data on record, last reported at $7.2 million in Q4 2025.

  • For Q4 2025, Payables rose 115.36% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $7.2 million, up 115.36%, while the annual FY2025 figure was $7.2 million, 115.36% up from the prior year.
  • Payables reached $7.2 million in Q4 2025 per RIGL's latest filing, up from $3.8 million in the prior quarter.
  • Across five years, Payables topped out at $15.0 million in Q4 2022 and bottomed at $1.7 million in Q2 2021.
  • Average Payables over 5 years is $5.5 million, with a median of $4.9 million recorded in 2021.
  • Peak YoY movement for Payables: skyrocketed 295.26% in 2022, then plummeted 57.37% in 2025.
  • A 5-year view of Payables shows it stood at $3.8 million in 2021, then surged by 295.26% to $15.0 million in 2022, then plummeted by 52.39% to $7.1 million in 2023, then plummeted by 53.25% to $3.3 million in 2024, then soared by 115.36% to $7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $7.2 million in Q4 2025, $3.8 million in Q3 2025, and $7.3 million in Q2 2025.